A5090753864- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Biosimilars and Bioanalytical Methods
- Neutropenia and Cancer Infections
- DNA Repair Mechanisms
- Inflammatory Biomarkers in Disease Prognosis
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Blood disorders and treatments
- Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Angiogenesis and VEGF in Cancer
- Chemotherapy-related skin toxicity
- Inflammatory Myopathies and Dermatomyositis
Ministry of Health
2019-2024
Ministry of Health of the Russian Federation
2017-2023
Russian Cancer Research Center NN Blokhin
2006-2023
ORCID
2021
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
Abstract Background: Trastuzumab deruxtecan (T-DXd) is approved in over 40 countries for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (a score 1+ on immunohistochemistry [IHC] analysis an IHC 2+ and negative results in-situ hybridization) breast cancer who have received prior chemotherapy setting developed disease recurrence during within 6 months completing adjuvant chemotherapy. DESTINY-Breast08 (DB-08) was designed to...
Abstract Background: Dose-dense neoadjuvant chemotherapy (NAC) provides the best efficacy results, irrespective of aPD-1 combinatory agent use for most aggressive subtype breast cancer - triple negative (TNBC). Maintaining relative dose intensity (RDI)≥85% NAC and RCB 0-1 achievement after are significantly associated with improvement patient’s prolonged long-term efficiency outcomes. Neutropenia is one keys limiting adverse event (AE) reducing RDI. Long-acting G-CSF an essential component...
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated alpelisib was developed by experts Russian Association Endocrinologists Society Clinical Oncology. contains recommendation risk assessment, prophylaxis regarding baseline metabolic status patients.
The polar division of breast cancer into HER2-positive and HER2-negative subtypes has long remained clinically significance. However, up to 60% tumors have HER2 receptor expression assessed by immunohistochemistry as 1+ or 2+. In the absence gene amplification, such are classified HER2-low. Сlassical anti-HER2 agents not improved treatment outcomes for these tumors. development a new generation antibody-cytostatic conjugate, trastuzumab deruxtecan, targeting receptor, is changing diagnostic...
Background. Assessment of hormone receptor status plays a crucial role in treatment patients with breast cancer. currently, clinicians are limited to determining the expression estrogen (ER), progesterone (pR) and HER2 only primary cancer tissues, even presence regional metastases. The purpose study was review available data on heterogeneity ER, pR HER2/neu expressions Material methods. We analyzed publications from pubmed, medline etc. using keywords «discordance», «breast cancer», «locally...
Abstract BACKGROUND Relative dose intensity (RDI) of chemotherapy (CT) < 85% significantly decrease therapy efficiency (including overall survival) in early breast cancer (BC) patients (pts). Pathological complete response (pCR) reflects better outcomes and correlates with the RDI neoadjuvant CT (NAC). Neutropenia is most common AE leading to drop. Recent studies are demonstrate that G-CSF could switch immunosuppressive tumor microenvironment via neutrophils plasticity. In BC...
e13035 Background: EMPOWER trial demonstrated the benefit of eribulin administrated post CD4/6i in patients (pts) with HR+ HER2-negative (HR+HER2-) metastatic breast cancer (MBC). There are several important limitations to this trial: > 60% pts were stage IV at time treatment initiation, used late lines (2L only 30% pts) and follow-up data immature. Current study aimed provide additional on real-world effectiveness safety monotherapy setting. Methods: Observation standard regimen enrolled...
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated alpelisib was developed by experts Russian Society Clinical Oncology dermatovenerologists. PIK3CA mutation is a poor prognostic factor for cancer. Alpelisib demonstrates efficacy mutation, but treatment might be associated adverse events that include rash. All-grade reported 35.6% SOLAR-1 trial (n=284). According to published real-world data, population (n=19) all-grade 37%...
Background . Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only new treatment regimens, but predictive and prognostic factors should developed. Materials methods We included 98 TN BC in our study. studied efficacy safety of PlaTax regimen (cisplatin 75 mg / m 2 day 1 + paclitaxel 80 days 1, 8, 15, course every 4 weeks) this cohort patients. assessed pathologic response, survival factors, which were relevant predicting...
Goal: To analyze the tumor response to NACT in patients with aggressive biological subtypes of stage II–III breast cancer based on contemporary scoring systems for residual pathological evaluation and burden according RCB system. Materials methods: A total 172 women (triple negative 34,3 %; HER2‑positive tumors 28,5 luminal B Her2‑negative BC 37,2 %) were included this analysis. The median age was 47 years (24–81 years); сT2 predominant size (65,1 %); 69,8 % had regional lymph node...
e12656 Background: The biosimilar of trastuzumab (Herticad ®) used in Russian clinical practice since March 2016, but the effectiveness, safety and economic rationality (BT) neoadjuvant chemotherapy HER2+ breast cancer (BC) have not been previously reported. Methods: In our study included 55 women with BC stage II-III treated National Research Cancer Center 2016 to December 2017 (median age- 52; range - 28-80 years). Neoadjuvant was all (sequential combination anthracyclines taxanes, AC→T...
Breast cancer steadily holds leading market positions in the malignancy morbidity and mortality pattern. The treatment of metastatic breast remains an extremely topical issue, when its aim is not only to prolong patient’s life, but also preserve quality. Due advances molecular diagnostics, it has become possible use several new classes drugs recent times. CDK4/6 inhibitors that demonstrate high efficacy first-line therapy for luminal one these groups. This review presents data from...
To evaluate the influence of clinical and morphological factors HER2 copy numbers on pathologic complete response (pCR) rates in patients with HER2-positive stage II-III breast cancer (BC).Treatment results were studied 73 Stage BC, who received treatment at N.N. Blokhin National Medical Research Center Oncology 2015 to 2018. Treatment included neoadjuvant chemotherapy (NACT) HER2-blockade radical surgery followed by evaluation a primary tumor regional lymph nodes. The patients` age varied...
Introduction. The presence of a germinal BRCA mutation occurs in 3–4% all breast cancer (BC) patients with various biological subtypes, but significantly high frequency triple negative subtype (in 10–20% cases). For the treatment HER2-negative metastatic associated gBRCA mutation, effectiveness biologically targeted drugs from group PARP inhibitors (olaparib and talazoparib) has been proven. P urpose. Comparison results our experience use talazoparib HER2-gBRCA+ + mBC data EMBRACA...
e12586 Background: TCHP is the standard regimen for neoadjuvant therapy (NAT) of HER2-positive early breast cancer (HER2+ eBC) and requires primary G-CSF prophylaxis (PP). Pathological complete response (pCR) after NAT reflects better pts outcomes. Long-acting presents more balanced neutrophils (NEU) count vs short G-CSF. Preclinical data show tumor-associated (TANs) as anti-tumor effector cells in eBC. There are limited on clinical benefit subset patients with HER2 amplification by ISH...
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. approval studies MONALEESA-2 7 demonstrated the efficacy safety ribociclib aromatase as first-line post- premenopausal patients. In Phase lllb CompLEEment-1 study, same regimen was evaluated an extended patient population terms both efficacy. article presents analysis data from subgroup...
Background. Breast cancer (BC) maintains the leading position in structure of morbidity and mortality from malignancies. Triple-negative BC (TNBC) is most aggressive subtype among all types BC. The adequate timely initiation neoadjuvant chemotherapy (NAC) determines further prognosis disease case early locally advanced TNBC. Patients over 60 years old are special subgroup, but it has not been previously considered separately. Aim. To determine efficacy NAC survival elderly patients with...
Background . The role of neoadjuvant chemotherapy (NACT) in luminal HER2-negative breast cancer (BC) remains highly controversial due to the lack reliable predictors drug therapy efficacy. Objective : evaluate effectiveness NACT patients with aggressive BC and compare modern systems for assessing pathomorphological response. Materials methods tumor response regimens was assessed 64 stage II–III. median age women 46.5 years (range 31–76 years), 76.6 % had primary operable stages (cT1–3N0–1),...
Understanding of cancer biology is at the cornerstone design new and effective treatment strategies. Identification molecular drivers tumor growth progression allow identify right patient for personalized plan optimization. Breast (BC) encompasses a heterogeneous collection neoplasms with diverse morphologies, phenotypes, responses to therapy, probabilities relapse overall survival. Molecular histopathological classification aims categories tumors into subgroups inform clinical decisions,...
Triple-negative breast cancer (TNBC) remains the most aggressive subtype of cancer. In presence distant metastases, median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group tumors, it includes both tumors sensitive to chemotherapy and that require targeted or immunotherapy for best treatment outcomes. Such features make difficult develop a single strategy all patients. Current perceptions resistance mechanisms molecular drivers progression have increased...